OMER - オメロス (Omeros Corporation)

OMERのニュース

   Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress  2020/06/11 12:45:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of the 25th annual European Hematology Association Congress. The presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, will be d
   Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress  2020/05/14 13:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually. The presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-
   Should You Buy Omeros (OMER) Ahead of Earnings?  2020/05/08 12:36:00 Zacks Investment Research
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020  2020/05/05 11:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone, ple
   Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results  2020/03/02 21:03:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
   Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results  2020/03/02 21:03:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
   Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA  2020/03/02 21:01:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and tr
   Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020  2020/02/24 12:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conferen
   Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors  2020/02/11 13:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role at Omeros. Mr. Zumwalt brings significant expertise in developing comprehensive business relationships with major banks and financial institutions. A 15-year veteran of Amazon, Mr. Zumwalt was responsible for managing the company’s cash, investments and debt financings, in
   The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares  2020/02/04 12:51:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 …
   Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results  2020/03/02 21:03:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
   Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA  2020/03/02 21:01:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and tr
   Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020  2020/02/24 12:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conferen
   Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors  2020/02/11 13:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role at Omeros. Mr. Zumwalt brings significant expertise in developing comprehensive business relationships with major banks and financial institutions. A 15-year veteran of Amazon, Mr. Zumwalt was responsible for managing the company’s cash, investments and debt financings, in
   The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares  2020/02/04 12:51:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 …

calendar